Association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use prior to major elective surgery and the risk of acute dialysis

Table 3 Propensity score matched cohort: association between preoperative ACEi/ARB use and outcomes

Outcomes	No. of patients with events (percent)		RR (95% CI)	ARR (95% CI)
	ACEi/ARB users	Non-users
	(N = 67,822)	(N = 67,822)
AKI-D	215 (0.32%)	278 (0.41%)	0.77 (0.65, 0.92)	0.09% (0.03%, 0.16%)
All-cause mortality	3,060 (4.51%)	3,295 (4.86%)	0.93 (0.88, 0.97)	0.35% (0.12%, 0.57%)

ACEi: Angiotensin converting enzyme inhibitor; ARB: Angiotensin receptor blocker; RR: Relative Risk; CI: Confidence Interval; ARR: Absolute risk reduction; AKI-D: Acute kidney injury treated with dialysis.
Outcomes: (1) Primary outcome: AKI-D (within 14 days after surgery); (2) Secondary outcome: All-cause mortality (within 90 days after surgery).
Relative risk was calculated for preoperative ACEi or ARB use compared to non-use.

ISSN: 1471-2369